Table 1.
Correlation between ID1 expression and whole AML as well as CN-AML patients parameters
| Patient’s parameters | Status of ID1 expression in whole AML | Status of ID1 expression in CN-AML | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Low (n=51) | High (n=51) | P | Low (n=27) | High (n=21) | P | |
| Sex, male/female | 29/22 | 32/19 | 0.687 | 15/12 | 16/5 | 0.224 |
| Median age, years (range) | 51 (10-93) | 60 (17-87) | 0.044 | 61 (15-86) | 61 (17-85) | 0.809 |
| Median WBC, ×109/L (range) | 5.7 (0.3-528.0) | 19.7 (1.1-185.4) | 0.062 | 10.2 (0.8-528.0) | 28.1 (1.2-136.1) | 0.330 |
| Median hemoglobin, g/L (range) | 78 (32-131) | 68 (40-138) | 0.095 | 88.5 (32-131) | 76.5 (40-138) | 0.492 |
| Median platelets, ×109/L (range) | 40 (6-140) | 42 (4-264) | 0.657 | 44.5 (6-140) | 30 (4-124) | 0.336 |
| BM blasts, % (range) | 44.0 (1.0-97.5) | 53.3 (3.0-109.0) | 0.132 | 51.8 (17.0-97.5) | 65.0 (6.0-109.0) | 0.778 |
| FAB | 0.450 | 0.542 | ||||
| M1 | 3 (6%) | 5 (10%) | 2 (7%) | 1 (5%) | ||
| M2 | 19 (37%) | 19 (37%) | 14 (52%) | 9 (43%) | ||
| M3 | 16 (31%) | 8 (16%) | - | - | ||
| M4 | 8 (16%) | 15 (29%) | 8 (30%) | 8 (38%) | ||
| M5 | 5 (10%) | 2 (4%) | 3 (11%) | 1 (5%) | ||
| M6 | 0 (0%) | 2 (4%) | 0 (0%) | 2 (9%) | ||
| WHO | 0.100 | 0.542 | ||||
| AML with t(8;21) | 3 (6%) | 4 (8%) | - | - | ||
| APL with t(15;17) | 16 (31%) | 8 (16%) | - | - | ||
| AML without maturation | 3 (6%) | 5 (10%) | 2 (7%) | 1 (5%) | ||
| AML with maturation | 16 (31%) | 15 (29%) | 14 (52%) | 9 (43%) | ||
| Acute myelomonocytic leukemia | 8 (16%) | 16 (31%) | 8 (30%) | 8 (38%) | ||
| Acute monoblastic and monocytic leukemia | 5 (10%) | 1 (2%) | 3 (11%) | 1 (5%) | ||
| Acute erythroid leukemia | 0 (0%) | 2 (4%) | 0 (0%) | 2 (9%) | ||
| Karyotype classification | 0.011 | - | ||||
| Favorable | 19 (37%) | 12 (23%) | - | - | ||
| Intermediate | 32 (63%) | 28 (55%) | - | - | ||
| Poor | 0 (0%) | 7 (14%) | - | - | ||
| No data | 0 (0%) | 4 (8%) | - | - | ||
| Karyotype | 0.033 | - | ||||
| normal | 27 (53%) | 21 (41%) | - | - | ||
| T (8; 21) | 3 (6%) | 4 (8%) | - | - | ||
| T (15; 17) | 16 (31%) | 8 (16%) | - | - | ||
| complex | 0 (0%) | 6 (12%) | - | - | ||
| others | 5 (10%) | 8 (16%) | - | - | ||
| No data | 0 (0%) | 4 (8%) | - | - | ||
| Gene mutation* | ||||||
| C/EBPA (+/-) | 6/42 (13%) | 4/44 (8%) | 0.740 | 4/23 (15%) | 3/17 (15%) | 1.000 |
| NPM1 (+/-) | 5/43 (10%) | 3/45 (6%) | 0.714 | 4/23 (15%) | 1/19 (5%) | 0.377 |
| FLT3 ITD (+/-) | 7/41 (15%) | 7/41 (15%) | 1.000 | 4/23 (15%) | 2/18 (10%) | 1.000 |
| C-KIT (+/-) | 0/48 (0%) | 0/48 (0%) | - | 0/27 (0%) | 0/20 (0%) | - |
| N/K RAS (+/-) | 4/44 (8%) | 5/43 (10%) | 1.000 | 4/23 (15%) | 2/18 (10%) | 1.000 |
| IDH1/2 (+/-) | 4/44 (8%) | 1/47 (2%) | 0.362 | 4/23 (15%) | 0/20 (0%) | 0.126 |
| DNMT3A (+/-) | 4/44 (8%) | 3/45 (6%) | 1.000 | 2/25 (7%) | 2/18 (10%) | 1.000 |
| U2AF1 (+/-) | 1/47 (2%) | 4/44 (8%) | 0.362 | 1/26 (4%) | 1/19 (5%) | 1.000 |
| CR (+/-) | 30/18 (63%) | 15/30 (33%) | 0.007 | 14/13 (52%) | 8/11 (42%) | 0.562 |
WBC, white blood cells; FAB, French-American-British classification; AML, acute myeloid leukemia; CR, complete remission;
*
percentage was equal to the number of mutated patients divided by total cases in each group.